Here are 1-3 brief analogies for Anika Therapeutics (ANIK):

• Zimmer Biomet for joint preservation with natural, injectable solutions.
• Amgen for hyaluronic acid-based therapies, targeting joint health and other medical applications.
• A specialized Medtronic focused on hyaluronic acid technology for joint pain and tissue repair.

```html

• Osteoarthritis (OA) Pain Management Products: This family includes products like Monovisc, Orthovisc, Cingal, and Hyvisc, indicated for pain relief from osteoarthritis conditions.
• Joint Preservation and Restoration Products: This category comprises bone preserving joint technologies, sports medicine soft tissue repair solutions, and orthopedic regenerative solutions.
• Non-Orthopedic HA-based Products: These are hyaluronic acid-based products for various applications outside orthopedics, such as adhesion barriers, advanced wound care, ophthalmic uses, and ear, nose, and throat treatments.

```

The provided background information does not name specific major customer companies for Anika Therapeutics. However, based on the description of its products (medical devices, treatments for osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving technologies), Anika Therapeutics primarily sells to other companies and organizations within the healthcare sector.

The major categories of its business customers include:

• Hospitals and Surgical Centers: These institutions utilize Anika's orthopedic, soft tissue repair, and regenerative solutions for surgical procedures and patient care.
• Clinics and Physician Offices: Particularly orthopedic clinics, rheumatology practices, and sports medicine practices, which administer Anika's OA pain management injections and other related treatments.
• Healthcare Distributors and Group Purchasing Organizations (GPOs): These intermediaries facilitate the sale and distribution of Anika's products to various healthcare facilities and systems.

null

Steve Griffin, President and Chief Executive Officer Mr. Griffin was appointed President and Chief Executive Officer of Anika Therapeutics, effective February 1, 2026, and also continues to act as the company's principal financial officer. He joined Anika in June 2024 as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, and was elevated to COO in April 2025. Prior to Anika, he served as Senior Vice President and Chief Financial Officer at VSE Corporation, where he was instrumental in executing a strategic transformation through organic growth, six acquisitions, and two divestitures. Before his tenure at VSE, Mr. Griffin spent over a decade at General Electric in various finance leadership roles, including Corporate Audit, Financial Planning and Analysis, and Divisional CFO roles across GE Healthcare, GE Aerospace, and GE Power. He is a graduate of GE's financial management program. David Colleran, Executive Vice President, General Counsel and Corporate Secretary David Colleran serves as Executive Vice President, General Counsel, and Corporate Secretary for Anika Therapeutics. Ian McLeod, Vice President, Chief Accounting Officer and Treasurer Ian McLeod holds the position of Vice President, Chief Accounting Officer, and Treasurer at Anika Therapeutics. Mira Leiwant, Senior Vice President, Regulatory, Quality and Clinical Affairs Mira Leiwant is the Senior Vice President of Regulatory, Quality, and Clinical Affairs at Anika Therapeutics. Dawn Wilson, Vice President, Research and Development Dawn Wilson serves as the Vice President of Research and Development for Anika Therapeutics.

Key Business Risks for Anika Therapeutics (ANIK)

1. Regulatory Hurdles and Product Development Risks: Anika Therapeutics faces significant risks related to the development and regulatory approval of its pipeline products, such as Cingal and Hyalofast. Delays or failures in obtaining FDA or international regulatory approvals, and challenges in clinical trials, could materially impact the company's competitive position and future financial results. For example, Hyalofast's U.S. Phase III trial did not meet its pre-specified co-primary endpoints, and the FDA has issued a deficiency letter regarding its PMA submission. Similarly, Cingal has faced a longer-than-expected pathway to commercialization in the United States, requiring additional bioequivalence work.

2. Competition and Pricing Pressure: The company operates in a highly competitive medical technology sector, particularly in its core areas of osteoarthritis (OA) pain management and regenerative solutions. Anika faces intense competition from larger, established players, which can negatively affect its market share and pricing power. This is evident in ongoing pricing pressures in the U.S. OA pain market, specifically within the OEM channel, which has led to projected declines in OEM channel revenue for products like Monovisc and Orthovisc due to revised pricing from its commercial partner.

3. Customer Concentration and Dependence on Strategic Partners: A substantial portion of Anika Therapeutics' revenue is derived from a limited number of customers and is heavily dependent on marketing and distribution partners. For instance, J&J MedTech accounted for 50% of revenue in 2025 and 57% in 2024. The loss of such key customers or changes in strategic partnership arrangements, particularly in the OEM channel where a commercial partner influences sales, marketing, and pricing, could materially and adversely affect the company's business, financial condition, and results of operations.

null

Anika Therapeutics operates in several key orthopedic care markets, including osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone-preserving joint technologies. The addressable markets for these main product areas are substantial both globally and within the United States. For **OA pain management**, the global osteoarthritis pain drugs market was valued at approximately USD 9.52 billion in 2025 and is projected to reach USD 14.33 billion by 2032. Another estimate places the global osteoarthritis treatment market at US$ 9.8 billion in 2025, with a projection to reach US$ 15.3 billion by 2032. In the United States, the osteoarthritis treatment market size was approximately USD 19 billion in 2023. In the realm of **regenerative solutions**, the global orthopedic regenerative surgical products market was estimated at USD 4.14 billion in 2022 and is expected to grow to USD 5.63 billion by 2030. More recent projections indicate the global market size at USD 4.56 billion in 2025, anticipated to increase to approximately USD 8.17 billion by 2035. North America is a dominant region within this market, accounting for over 42% of the revenue share in 2025. The **soft tissue repair** market globally was valued at USD 14.65 billion in 2023 and is projected to reach USD 22.89 billion by 2030. Another report valued the global soft tissue repair market at USD 15.51 billion in 2025, with an estimated growth to USD 20.33 billion by 2031. North America held a significant share of this market, with 46.25% in 2023, and the U.S. market alone dominated North America with an 89.3% revenue share in the same year. For **bone-preserving joint technologies**, which encompasses joint reconstruction and bone regeneration, the global joint reconstruction devices market was valued at USD 28.91 billion in 2024 and is expected to reach USD 41.23 billion by 2033. The United States alone represented a significant portion of this market, with a value of USD 12.54 billion in 2024, projected to reach USD 13 billion in 2025. The global bone regeneration material market size was calculated at USD 3.85 billion in 2024 and is projected to reach approximately USD 8.87 billion by 2034. Additionally, the global bone replacement market is expected to be around USD 29.9 billion by 2033, up from USD 17.2 billion in 2023. The global bone grafts and substitutes market was estimated at USD 3.34 billion in 2025 and is projected to reach USD 5.50 billion by 2033. North America held the largest share of the bone grafts and substitutes market with 41.96% in 2025.

Anika Therapeutics (ANIK) is expected to drive future revenue growth over the next two to three years through several key initiatives and product advancements:

• Growth in the Commercial Channel, especially International OA Pain Management: Anika anticipates continued strong performance from its commercial channel, particularly in international osteoarthritis (OA) pain management. Products such as Monovisc, Orthovisc, and Cingal are expected to maintain and expand market share through geographic expansion. The commercial channel has consistently delivered robust growth, with a 25% increase in Q4 2024 and 17% for the full year 2024, and 18% in Q1 2025, driven by international OA pain management. The company expects commercial channel revenue to grow 12% to 18% year-over-year in 2025, and 10% to 20% in 2026.
• Increased Adoption and Expansion of the Integrity™ Implant System: The Integrity Implant System is a significant driver within Anika's regenerative solutions portfolio. It has demonstrated consistent sequential growth, with procedures and revenue more than doubling in 2025. The company highlights its expanding surgeon adoption and market penetration as key growth factors.
• U.S. Launch and Adoption of Hyalofast: Anika is actively progressing towards the U.S. launch of Hyalofast. Regulatory milestones, including MDR approval and the filing of PMA modules, have been achieved, with the third and final PMA module on track for submission in the second half of 2025. A U.S. launch is anticipated in 2026, with an expected revenue contribution in 2027.
• U.S. NDA Filing and Potential Launch of Cingal: Anika has received formal written feedback from the FDA regarding Cingal, which has cleared the path for its New Drug Application (NDA) filing following the completion of a bioequivalence bridging study. The successful completion of this study and subsequent NDA filing would open the door for a potential U.S. launch, contributing to future revenue.
• Strategic Realignment and Focus on Core Orthopedic Markets: The company has strategically refocused its resources on high-opportunity areas within orthopedics, specifically OA pain management and regenerative solutions. This includes the divestiture of non-core assets like Arthrosurface and Parcus Medical to streamline operations and enhance returns. This sharpened focus is expected to improve revenue diversification and concentrate efforts on more profitable growth areas.

Share Repurchases

• Anika Therapeutics initiated a stock repurchase program in May 2024, utilizing $10.9 million to repurchase shares.
• A $50 million share repurchase program was authorized in May 2019, comprising $30 million through an accelerated share repurchase (ASR) program and $20 million on the open market, with completion anticipated by the second quarter of 2020.

Share Issuance

• Anika Therapeutics had approximately 14.18 million shares of common stock outstanding as of March 6, 2025.
• The company reported 14.85 million shares of common stock outstanding as of March 6, 2024.

Outbound Investments

• In October 2024, Anika Therapeutics announced a strategic shift to concentrate on OA Pain Management and Regenerative Solutions, leading to the sale of Arthrosurface Incorporated on October 31, 2024.
• The divestiture of Parcus Medical, LLC to Medacta Group SA was completed on March 7, 2025, for an undisclosed cash consideration.

Capital Expenditures

• Anika Therapeutics' capital expenditures for the full year 2025 amounted to $6.8 million.
• In Q4 2025, the company invested $648,000 in capital expenditures.
• The company plans to continue investing in research and development for new products and clinical trials related to its hyaluronic acid-based technology.